PMID- 35589615
OWN - NLM
STAT- MEDLINE
DCOM- 20220803
LR  - 20221015
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 24
IP  - 9
DP  - 2022 Sep
TI  - Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult 
      patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
PG  - 1869-1881
LID - 10.1111/dom.14776 [doi]
AB  - AIMS: To determine the effect of glucagon-like peptide 1 receptor agonists 
      (GLP-1RAs) on albuminuria in adult patients with type 2 diabetes mellitus (T2DM). 
      METHODS: Medline Ovid, Scopus, Web of Science, EMCARE and CINAHL databases from 
      database inception until 27 January 2022. Studies were eligible for inclusion if 
      they were randomized controlled trials that involved treatment with a GLP-1RA in 
      adult patients with T2DM and assessed the effect on albuminuria in each treatment 
      arm. Data extraction was conducted independently by three individual reviewers. 
      The PRISMA guidelines were followed regarding data extraction and quality 
      assessment. Data were pooled using a random effects inverse variance model and 
      all analysis was carried out with RevMan 5.4 software. The Jadad scoring tool was 
      employed to assess the quality of evidence and risk of bias in the randomized 
      controlled trials. RESULTS: The initial search revealed 2419 articles, of which 
      19 were included in this study. An additional three articles were identified from 
      hand-searching references of included reviews. Therefore, in total, 22 articles 
      comprising 39 714 patients were included. Meta-analysis suggested that use of 
      GLP1-RAs was associated with a reduction in albuminuria in patients with T2DM 
      (weighted mean difference -16.14%, 95% CI -18.42 to -13.86%; p < .0001) compared 
      with controls. CONCLUSIONS: This meta-analysis indicates that GLP-1RAs are 
      associated with a significant reduction in albuminuria in adult patients with 
      T2DM when compared with placebo.
CI  - (c) 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Yuan, Daniel
AU  - Yuan D
AUID- ORCID: 0000-0002-9426-6146
AD  - Translational Research in Endocrinology and Diabetes (TREAD), College of Medicine 
      and Dentistry, James Cook University, Douglas, Queensland, Australia.
AD  - College of Medicine and Dentistry, James Cook University, Douglas, Queensland, 
      Australia.
FAU - Sharma, Harman
AU  - Sharma H
AUID- ORCID: 0000-0002-9274-4669
AD  - College of Medicine and Dentistry, James Cook University, Douglas, Queensland, 
      Australia.
FAU - Krishnan, Anirudh
AU  - Krishnan A
AD  - College of Medicine and Dentistry, James Cook University, Douglas, Queensland, 
      Australia.
FAU - Vangaveti, Venkat N
AU  - Vangaveti VN
AUID- ORCID: 0000-0002-4363-309X
AD  - Translational Research in Endocrinology and Diabetes (TREAD), College of Medicine 
      and Dentistry, James Cook University, Douglas, Queensland, Australia.
AD  - College of Medicine and Dentistry, James Cook University, Douglas, Queensland, 
      Australia.
FAU - Malabu, Usman H
AU  - Malabu UH
AUID- ORCID: 0000-0003-4899-7228
AD  - Translational Research in Endocrinology and Diabetes (TREAD), College of Medicine 
      and Dentistry, James Cook University, Douglas, Queensland, Australia.
AD  - College of Medicine and Dentistry, James Cook University, Douglas, Queensland, 
      Australia.
AD  - Townsville University Hospital, Douglas, Queensland, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220606
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Albuminuria/complications/drug therapy
MH  - *Diabetes Mellitus, Type 2/chemically induced/complications/drug therapy
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Randomized Controlled Trials as Topic
PMC - PMC9541913
COIS- The authors declare that they have no competing interests.
EDAT- 2022/05/20 06:00
MHDA- 2022/08/04 06:00
PMCR- 2022/10/07
CRDT- 2022/05/19 22:32
PHST- 2022/05/02 00:00 [revised]
PHST- 2022/02/28 00:00 [received]
PHST- 2022/05/17 00:00 [accepted]
PHST- 2022/05/20 06:00 [pubmed]
PHST- 2022/08/04 06:00 [medline]
PHST- 2022/05/19 22:32 [entrez]
PHST- 2022/10/07 00:00 [pmc-release]
AID - DOM14776 [pii]
AID - 10.1111/dom.14776 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2022 Sep;24(9):1869-1881. doi: 10.1111/dom.14776. Epub 2022 
      Jun 6.